Lack of Efficacy of Interferon-α Therapy in Recurrent, Advanced Cervical Cancer

Scott Wadler, Peter H. Wiernik, Scott Wadler, Robert D. Burk, Carolyn D. Runowicz, Gary Goldberg, Frances McGill, Robert D. Burk, Ruth Tachezy, Donna Neuberg, Ronalde Rameau, Robert Comis, John Edmonson, Peter H. Wiernik

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Human papillomavirus (HPV) is associated with 65-95% of in situ or early invasive squamous cell carcinomas of the cervix. A multiinstitutional, prospective phase II clinical trial was initiated by the Eastern Cooperative Oncology Group (ECOG) to study the activity of IFN-α2b in women with metastatic or locally recurrent cervix cancer. The activity of IFN-α2b was correlated with the presence of HPV as measured by Southern blot hybridization or polymerase chain reaction techniques in 17 patients. All patients had failed prior definitive therapy with surgery, radiation, and chemotherapy. IFN-α2b was administered at 10 MU/m2 subcutaneously three times per week. Among 31 patients enrolled, 3 achieved a clinical response to treatment. Tumor was accessible for biopsy in 17 patients. The presence of HPV was assayed by Southern blot hybridization (2 of 17) and/or polymerase chain reaction (PCR) technology (15 of 17). Of the 17 assays, 16 were informative. HPV was detected in 5 of 16 patients. Of 5 HPV-positive women, 2 responded to treatment, versus 1 of 11 HPV-negative women, thus not permitting reliable statistical analysis. It is concluded that IFN-α2b has only minimal activity against advanced, recurrent cervical cancer.

Original languageEnglish (US)
Pages (from-to)1011-1016
Number of pages6
JournalJournal of Interferon and Cytokine Research
Issue number12
StatePublished - Dec 1995

ASJC Scopus subject areas

  • Immunology
  • Cell Biology
  • Virology


Dive into the research topics of 'Lack of Efficacy of Interferon-α Therapy in Recurrent, Advanced Cervical Cancer'. Together they form a unique fingerprint.

Cite this